References
- Bartlett JG, Mundy LM. Community-acquired pneumo-nia. N Engl J Med 1995; 333: 1618–1624.
- Donowitz GR, Mandell GL. Acute pneumonia. In: Mandell GL, Bennett JE, Raphael D, eds, Principles and prac-tice in infectious diseases. 4th ed. Vol. 1. New York: Churchill Livingstone, 1995: 619-637.
- Marrie TJ, Haldane EV, Noble MA, Faulkner RS, Martin RS, Lee SHS. Causes of atypical pneumonia: results of a 1-year prospective study. Can Med Assoc J 1981; 125: 1118-1123.
- Schlick W. The problems of treating atypical pneumo-nia. J Antimicrob Chemother 1993; 31: Suppl C: 111-120.
- Wise R. The pharmacokinetics of azithromycin. Rev Contemp Pharmacother 1994; 5: 329–340.
- Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. Azithromycin concentrations at the sites of pulmonary infections. Eur Respir J 1990; 3: 886–890.
- Morris DI, De Souza A, Jones JA, Morgan WE. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur J Clin Microbiol Infect Dis 1991; 10: 859–861.
- Foulds G, Shepard RM, Johnson RB. The pharmacoki-netics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25: Suppl A: 73-82.
- Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother 1990; 25: Suppl A: 39-50.
- Welsh LE, Gaydos CA, Quinn TC. In vitro evaluation of activities of azithromycin, erythromycin and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 291–294.
- Renaudin H, Bebear C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 1990; 9: 838–841.
- Edelstein PH. Antimicrobial chemotherapy for legion-naires' disease: a review. Clin Infect Dis 1995; 21: Suppl C: S265-276.
- Fitzgeorge RB, Featherstone ASR, Baskerville A. Efficacy of azithromycin in the treatment of guinea pigs infect-ed with Legionella pneumophila by aerosol. J Antimicrob Chemother 1990; 25: Suppl A: 101-108.
- Hoepelman AIM, Sips AP, van Helmond JLM et al. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infec-tions. J Antimicrob Chemother 1993; 25: Suppl E: 147-152.
- Bradbury F. Comparison of azithromycin versus clar-ithromycin in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993; 25: Suppl E: 153-162.
- Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1991; 10: 872–876.
- Myburgh J, Nagel GJ, Petschel E. The efficacy and tol-erance of a three-day course of azithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1993; 25: Suppl E: 163-169.
- Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gogev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonia. J Antimicrob Chemother 1990; 25: Suppl A: 101-108.
- Schonwald S, gkerk V, Petricevic I, Car V, Majerus-Mi_ic II, Gunjaca M. Comparison of three-day and five-day azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis 1991; 10: 877–880.
- Kuzman I, Soldo I, Schonwald S, Culig J. Azithromycin for treatment of community-acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis 1995; 27: 503–505.
- Raoult D, Torres H, Drancourt M. Shell-vial assay: eval-uation of new technique for determining antibiotic susceptibili-ty, tested in 13 isolates of Coxiella burnetii. Antimicrob Agents Chemother 1991; 35: 2070–2077.
- Marrie TJ. Coxiella burnetii (Q fever) pneumonia. Clin Infect Dis 1995; 21: Suppl 3: S253–64.
- Perez-del-Molino A, Aguado JM, Riancho JA, Sampedro I, Matorras P, Gonzales-Macias J. Erythromycin and the treatment of Coxiella burnetii pneumonia. J Antimicrob Chemother 1991; 28: 455–459.